{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:47:09Z","timestamp":1789958829290,"version":"4.0.1"},"reference-count":47,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,5,9]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Independent predictors of stable, undetectable BCR-ABL1 during first-line imatinib therapy were female sex and the BCR-ABL1 value at 3 months. Time to achieve an MMR influenced time to stable, undetectable BCR-ABL1, suggesting slower dynamics of BCR-ABL1 decline with delayed MMR.<\/jats:p>","DOI":"10.1182\/blood-2012-10-462291","type":"journal-article","created":{"date-parts":[[2013,3,21]],"date-time":"2013-03-21T02:27:44Z","timestamp":1363832864000},"page":"3818-3824","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":154,"title":["Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML"],"prefix":"10.1182","volume":"121","author":[{"given":"Susan","family":"Branford","sequence":"first","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"},{"name":"School of Medicine,"},{"name":"School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Yeung","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"},{"name":"School of Medicine,"},{"name":"Department of Haematology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Ross","sequence":"additional","affiliation":[{"name":"School of Medicine,"},{"name":"Department of Haematology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"},{"name":"Department of Haematology and Genetic Pathology, Flinders University and Medical Centre, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi A.","family":"Prime","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chani R.","family":"Field","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley K.","family":"Altamura","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra L.","family":"Yeoman","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Georgievski","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronte A.","family":"Jamison","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Phillis","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy E.","family":"Briggs","sequence":"additional","affiliation":[{"name":"Discipline of Public Health, University of Adelaide, Adelaide, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hertzberg","sequence":"additional","affiliation":[{"name":"Australasian Leukaemia and Lymphoma Group, East Melbourne, Australia;"},{"name":"Westmead Hospital, Westmead and The University of Sydney, Sydney, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[{"name":"Australasian Leukaemia and Lymphoma Group, East Melbourne, Australia;"},{"name":"Peter MacCallum Cancer Centre, East Melbourne, and University of Melbourne, Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Faculty of Health, Deakin University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"School of Medicine,"},{"name":"Department of Haematology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia;"},{"name":"Australasian Leukaemia and Lymphoma Group, East Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111820404106200_B1","author":"Deininger"},{"issue":"17","key":"2019111820404106200_B2","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2019111820404106200_B3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"10","key":"2019111820404106200_B4","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"key":"2019111820404106200_B5","author":"Mahon"},{"issue":"suppl 1","key":"2019111820404106200_B6","first-page":"74","article-title":"Frequent and sustained drug-free remission in the Australian CML8 trial of imatinib withdrawal. [abstract 0189]","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"issue":"6","key":"2019111820404106200_B7","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1080\/10428190902926973","article-title":"Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy.","volume":"50","author":"Goh","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2019111820404106200_B8","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2010-04-280206","article-title":"Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response.","volume":"116","author":"Kuwabara","year":"2010","journal-title":"Blood"},{"issue":"23","key":"2019111820404106200_B9","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","article-title":"BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.","volume":"13","author":"Branford","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111820404106200_B10","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","article-title":"Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.","volume":"17","author":"Branford","year":"2003","journal-title":"Leukemia"},{"issue":"3","key":"2019111820404106200_B11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","article-title":"Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111820404106200_B12","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg\/day of imatinib as initial therapy.","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"2019111820404106200_B13","author":"Yeung"},{"issue":"3","key":"2019111820404106200_B14","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","article-title":"Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics.","volume":"107","author":"Branford","year":"1999","journal-title":"Br J Haematol"},{"issue":"15","key":"2019111820404106200_B15","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111820404106200_B16","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1038\/leu.2011.116","article-title":"Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.","volume":"25","author":"Pfirrmann","year":"2011","journal-title":"Leukemia"},{"issue":"25","key":"2019111820404106200_B17","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1182\/blood-2011-10-383711","article-title":"Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.","volume":"119","author":"Guilhot","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111820404106200_B18","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk.","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"446","key":"2019111820404106200_B19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"6","key":"2019111820404106200_B20","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","article-title":"The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.","volume":"120","author":"Wang","year":"2003","journal-title":"Br J Haematol"},{"issue":"19","key":"2019111820404106200_B21","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111820404106200_B22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111820404106200_B23","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"2019111820404106200_B24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","article-title":"Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.","volume":"120","author":"Marin","year":"2012","journal-title":"Blood"},{"issue":"35","key":"2019111820404106200_B25","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","article-title":"Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.","volume":"30","author":"Branford","year":"2012","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111820404106200_B26","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111820404106200_B27","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111820404106200_B28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"2019111820404106200_B29","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111820404106200_B30","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3324\/haematol.2011.045666","article-title":"Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.","volume":"97","author":"Guilhot","year":"2012","journal-title":"Haematologica"},{"issue":"11","key":"2019111820404106200_B31","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1182\/blood-2007-12-128397","article-title":"Development and dynamics of robust T-cell responses to CML under imatinib treatment.","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"issue":"1689","key":"2019111820404106200_B32","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1098\/rspb.2009.2179","article-title":"Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses.","volume":"277","author":"Wodarz","year":"2010","journal-title":"Proc Biol Sci"},{"issue":"2","key":"2019111820404106200_B33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2141.1989.tb07674.x","article-title":"Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial.","volume":"72","author":"Catovsky","year":"1989","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111820404106200_B34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00432-002-0408-4","article-title":"Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy.","volume":"129","author":"Jeremic","year":"2003","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"2019111820404106200_B35","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.ophtha.2004.04.016","article-title":"Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.","volume":"111","author":"G\u00fcnd\u00fcz","year":"2004","journal-title":"Ophthalmology"},{"issue":"2","key":"2019111820404106200_B36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1023\/A:1026533016912","article-title":"Surgery, tamoxifen, carboplatin, and radiotherapy in the treatment of newly diagnosed glioblastoma patients.","volume":"49","author":"Puchner","year":"2000","journal-title":"J Neurooncol"},{"issue":"4","key":"2019111820404106200_B37","first-page":"335","article-title":"Review of erlotinib in the treatment of advanced non-small cell lung cancer.","volume":"1","author":"Ganjoo","year":"2007","journal-title":"Biologics"},{"issue":"7046","key":"2019111820404106200_B38","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia.","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"issue":"10","key":"2019111820404106200_B39","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","article-title":"Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.","volume":"12","author":"Roeder","year":"2006","journal-title":"Nat Med"},{"issue":"21","key":"2019111820404106200_B40","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-11-0396","article-title":"BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.","volume":"17","author":"Stein","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111820404106200_B41","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1182\/blood-2011-02-339267","article-title":"Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells.","volume":"118","author":"Tang","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111820404106200_B42","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.leukres.2012.02.011","article-title":"Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response.","volume":"36","author":"Yhim","year":"2012","journal-title":"Leuk Res"},{"issue":"suppl 1","key":"2019111820404106200_B43","first-page":"80","article-title":"BCR-ABL kinetics after discontinuation of imatinib in CML patients with MR 4.5 or undetectable molecular residual disease. [abstract 0200]","volume":"97","author":"Lee","year":"2012","journal-title":"Haematologica"},{"issue":"10","key":"2019111820404106200_B44","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia.","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"2019111820404106200_B45","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"issue":"5","key":"2019111820404106200_B46","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"2019111820404106200_B47","author":"Rea"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/19\/3818\/1218520\/3818.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/19\/3818\/1218520\/3818.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T04:22:14Z","timestamp":1595564534000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/121\/19\/3818\/105667\/Early-molecular-response-and-female-sex-strongly"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,9]]},"references-count":47,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2013,5,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-10-462291","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,9]]}}}